Nesiritide during extracorporeal membrane oxygenation.

Abstract

Nesiritide is a recombinant formulation of B-type natriuretic peptide (BNP). Preliminary experience in the adult population has shown nesiritide to be an effective agent in the treatment of decompensated congestive heart failure (CHF) in adults. Given its physiological effects, it may be an effective agent in other clinical scenarios. We report the use of nesiritide in two infants during extracorporeal membrane oxygenation (ECMO). In one patient, nesiritide in doses up to 0.09 microg.kg(-1).min(-1) were used to control mean arterial pressure while in the other patient, doses of 0.01-0.03 microg.kg(-1).min(-1) were used to augment urine output. The potential applications of nesiritide and dosing regimens for this agent in the ECMO population are discussed.

• Authors: Todd Smith, David A Rosen, Pierantonio Russo, John W Berkenbosch, Robert A Gustafson, Benjamin L Siu, Kathleen R Rosen, Joseph D Tobias
• Journal: Paediatric anaesthesia (Paediatr Anaesth) Vol. 15 Issue 2 Pg. 152-7 (Feb 2005) ISSN: 1155-5645 [Print] France
• PMID: 15675934 (Publication Type: Case Reports, Journal Article)

Chemical References

• Natriuretic Agents
• Natriuretic Peptide, Brain

Topics

• Blood Pressure (drug effects)
• Cardiopulmonary Resuscitation (methods)
• Dose-Response Relationship, Drug
• Electrocardiography (methods)
• Extracorporeal Membrane Oxygenation (adverse effects)
• Fatal Outcome
• Heart Diseases (complications, therapy)
• Heart Ventricles (physiopathology)
• Hernia, Diaphragmatic (complications, surgery)
• Humans
• Hypertension (complications, drug therapy)
• Hypokinesia (complications, diagnosis)
• Hypoplastic Left Heart Syndrome (complications, surgery)
• Infant, Newborn
• Male
• Natriuretic Agents (therapeutic use)
• Natriuretic Peptide, Brain (therapeutic use)
• Respiratory Insufficiency (complications, therapy)
• Urination (drug effects)